keyword
MENU ▼
Read by QxMD icon Read
search

Type 2 diabetes and basal insulin

keyword
https://www.readbyqxmd.com/read/28643425/ideglira-was-effective-across-a-range-of-dysglycaemia-and-bmi-categories-in-the-dual-v-randomized-trial
#1
Ildiko Lingvay, Stewart Harris, Elmar Jaeckel, Keval Chandarana, Mattis F Ranthe, Esteban Jódar
This study assessed the efficacy of insulin degludec/liraglutide (IDegLira) versus insulin glargine U100 (IGlar) across categories of baseline HbA1c (≤7.5%, >7.5- ≤ 8.5% and >8.5%), body mass index (BMI; <30, ≥30- < 35 and ≥35 kg/m(2) ) and fasting plasma glucose (FPG; <7.2 and ≥7.2 mmol/L) in patients with type 2 diabetes (T2D) uncontrolled on basal insulin, using post hoc analyses of the DUAL V 26-week trial. With IDegLira, mean HbA1c was reduced across all baseline HbA1c (1...
June 23, 2017: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/28643293/-why-is-a-combination-of-basal-insulin-with-a-glp-1-receptor-agonist-useful-in-many-patients-with-type-2-diabetes
#2
Michael Nauck, Birgit Wilhelm
BACKGROUND: In 2015, the combination of basal insulin and GLP-1 receptor agonist (RA) was incorporated into the guideline recommendations for type 2 diabetes as an option for the last escalation step. The two antidiabetics to be injected subcutaneously are complementary regarding their respective main effects and limitations. Basal insulin is predominantly active between meals and in the fasting state, whereas the main action of GLP-1 RA consists in preventing an excessive postprandial blood glucose increase...
June 2017: MMW Fortschritte der Medizin
https://www.readbyqxmd.com/read/28626803/estimation-of-insulin-secretion-glucose-uptake-by-tissues-and-liver-handling-of-glucose-using-a-mathematical-model-of-glucose-insulin-homeostasis-in-lean-and-obese-mice
#3
Michael Brenner, Sakineh Esmaeili Mohsen Abadi, Ramin Balouchzadeh, H Felix Lee, Hoo Sang Ko, Michael Johns, Nehal Malik, Joshua J Lee, Guim Kwon
Destruction of the insulin-producing β-cells is the key determinant of diabetes mellitus regardless of their types. Due to their anatomical location within the islets of Langerhans scattered throughout the pancreas, it is difficult to monitor β-cell function and mass clinically. To this end, we propose to use a mathematical model of glucose-insulin homeostasis to estimate insulin secretion, glucose uptake by tissues, and hepatic handling of glucose. We applied the mathematical model by Lombarte et al. (2013) to compare various rate constants representing glucose-insulin homeostasis between lean (11% fat)- and high fat diet (HFD; 45% fat)-fed mice...
June 2017: Heliyon
https://www.readbyqxmd.com/read/28622950/glycaemic-control-and-hypoglycaemia-with-insulin-glargine-300u-ml-versus-insulin-glargine-100u-ml-in-insulin-na%C3%A3-ve-people-with-type-2%C3%A2-diabetes-12-month-results-from-the-edition-3-trial
#4
G B Bolli, M C Riddle, R M Bergenstal, M Wardecki, H Goyeau, P D Home
AIM: To explore if efficacy and safety findings for insulin glargine 300U/mL (Gla-300) versus insulin glargine 100U/mL (Gla-100), observed over 6 months in insulin-naïve people with type 2 diabetes, are maintained after 12 months. METHODS: EDITION 3 was a phase 3a, randomized, multicentre, open-label, parallel-group, treat-to-target study of once-daily Gla-300 versus Gla-100 (target fasting self-monitored plasma glucose, 4.4-5.6mmol/L [80-100mg/dL]). Participants completing the initial 6-month treatment phase continued their previously allocated basal insulin...
June 13, 2017: Diabetes & Metabolism
https://www.readbyqxmd.com/read/28618984/glycemic-variability-and-insulin-needs-in-patients-with-type-1-diabetes-mellitus-supplemented-with-vitamin-d-a-pilot-study-using-continuous-glucose-monitoring-system
#5
Karem Miléo Felício, Ana Carolina Contente Braga de Souza, João Felício Abrahão Neto, Franciane Trindade Cunha de Melo, Carolina Tavares Carvalho, Thaís Pontes Arbage, Hana Andrade de Rider Brito, Amanda Soares Peixoto, Alana Ferreira de Oliveira, Fabricio de Souza Resende, Scarlatt Sousa Reis, Ana Regina Motta, Henrique da Costa Miranda, Luísa Corrêa Janaú, Elizabeth Sumi Yamada, João Soares Felício
BACKGROUND: Recent studies suggest that glycemic variability could influence the risk of complications in type 1 diabetes mellitus (T1DM). There are no data about the action of vitamin D (VD) on glycemic variability. Our pilot study aims to evaluate glycemic variability and insulin needs in patients with T1DM supplemented with VD. METHODS: 22 patients received doses of 4000 and 10000 IU/day of cholecalciferol for 12 weeks, according to the patient's baseline VD levels and underwent continuous glucose monitoring system...
June 15, 2017: Current Diabetes Reviews
https://www.readbyqxmd.com/read/28615237/erratum-combination-therapy-with-exenatide-plus-pioglitazone-versus-basal-bolus-insulin-in-patients-with-poorly-controlled-type-2-diabetes-on-sulfonylurea-plus-metformin-the-qatar-study-diabetes-care-2017-40-325-331
#6
Muhammad Abdul-Ghani, Osama Migahid, Ayman Megahed, John Adams, Curtis Triplitt, Ralph A DeFronzo, Mahmoud Zirie, Amin Jayyousi
No abstract text is available yet for this article.
June 14, 2017: Diabetes Care
https://www.readbyqxmd.com/read/28605603/efficacy-and-safety-of-degludec-versus-glargine-in-type-2-diabetes
#7
Steven P Marso, Darren K McGuire, Bernard Zinman, Neil R Poulter, Scott S Emerson, Thomas R Pieber, Richard E Pratley, Poul-Martin Haahr, Martin Lange, Kirstine Brown-Frandsen, Alan Moses, Simon Skibsted, Kajsa Kvist, John B Buse
Background Degludec is an ultralong-acting, once-daily basal insulin that is approved for use in adults, adolescents, and children with diabetes. Previous open-label studies have shown lower day-to-day variability in the glucose-lowering effect and lower rates of hypoglycemia among patients who received degludec than among those who received basal insulin glargine. However, data are lacking on the cardiovascular safety of degludec. Methods We randomly assigned 7637 patients with type 2 diabetes to receive either insulin degludec (3818 patients) or insulin glargine U100 (3819 patients) once daily between dinner and bedtime in a double-blind, treat-to-target, event-driven cardiovascular outcomes trial...
June 12, 2017: New England Journal of Medicine
https://www.readbyqxmd.com/read/28605286/the-durability-of-basal-insulin-affects-day-to-day-glycemic-variability-assessed-by-continuous-glucose-monitoring-in-type-2-diabetes-patients-a-randomized-crossover-trial
#8
Hiroyuki Iuchi, Masaya Sakamoto, Daisuke Matsutani, Hirofumi Suzuki, Ryuzo Horiuchi, Kazunori Utsunomiya
BACKGROUND: Not only within-day glycemic variability but also day-to-day glycemic variability is a risk factor for diabetic patients. However, the ways of controlling day-to-day glycemic variability are unclear. We hypothesized that the durability of basal insulin plays an important role in controlling day-to-day glycemic variability in type 2 diabetes patients, and we therefore aimed to evaluate whether glargine U300, which exhibits prolonged absorption compared with glargine U100 but the same composition as glargine U100, would lead to improved day-to-day glycemic variability...
June 12, 2017: Diabetes Technology & Therapeutics
https://www.readbyqxmd.com/read/28604759/markers-of-maternal-and-infant-metabolism-are-associated-with-ventricular-dysfunction-in-infants-of-obese-women-with-type-2-diabetes
#9
W Todd Cade, Philip T Levy, Rachel A Tinius, Mehgna D Patel, Swati Choudhry, Mark R Holland, Gautam K Singh, Alison G Cahill
BACKGROUND: To test the hypothesis that infants born to obese women with pregestational type 2 diabetes mellitus (IBDM) have ventricular dysfunction at one month that is associated with markers of maternal lipid and glucose metabolism. METHODS: In a prospective observational study of IBDM (OB+DM, n=25), echocardiography measures of septal, left (LV) and right ventricular (RV) function and structure were compared at one month of age to infants born to OB mothers without DM (OB, n=24), and non-OB without DM (Lean, n=23)...
June 12, 2017: Pediatric Research
https://www.readbyqxmd.com/read/28604112/correlates-of-basal-insulin-persistence-among-insulin-na%C3%A3-ve-people-with-type-2-diabetes-results-from-a-multi-national-survey
#10
Mark Peyrot, Magaly Perez-Nieves, Jasmina Ivanova, Dachuang Cao, Luke Schmerold, Samaneh Kalirai, Irene Hadjiyianni
BACKGROUND AND OBJECTIVE: People with T2DM who initiate basal insulin therapy often stop therapy temporarily or permanently soon after initiation. This study analyzes the reasons for and correlates of stopping and restarting basal insulin therapy among people with T2DM. METHODS: An online survey was completed by 942 insulin-naïve adults with self-reported T2DM from Brazil, France, Germany, Japan, Spain, UK, and US. Respondents had initiated basal insulin therapy within the 3-24 months before survey participation and met criteria for one of three persistence groups: continuers had no gaps of ≥7 days in basal insulin treatment; interrupters had at least one gap in insulin therapy of ≥7 days within the first 6 months after initiation and had since restarted basal insulin; and discontinuers stopped using basal insulin within the first 6 months after initiation and had not restarted...
June 10, 2017: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/28604111/basal-insulin-initiation-use-and-experience-among-people-with-type-2-diabetes-mellitus-with-different-patterns-of-persistence-results-from-a-multi-national-survey
#11
Magaly Perez-Nieves, Jasmina I Ivanova, Irene Hadjiyianni, Chen Zhao, Dachuang Cao, Luke Schmerold, Samaneh Kabul, Sarah King, Amy M DeLozier, Howard G Birnbaum, Mark Peyrot
BACKGROUND AND OBJECTIVE: People with type 2 diabetes mellitus (T2DM) often interrupt basal insulin treatment soon after initiation. This study aimed to describe the experiences during and after basal insulin initiation among people with T2DM with different persistence patterns. METHODS: Adults with T2DM from France, Germany, Spain, UK, US, Brazil, and Japan were identified from consumer panels for an online survey. Respondents who initiated basal insulin 3-24 months prior to survey date,were categorized as continuers (no gaps of ≥7 days in insulin treatment); interrupters (first gap ≥7 days within 6 months of initiation and restarted insulin); and discontinuers (stopped insulin for ≥7 days within 6 months of initiation without restarting)...
June 10, 2017: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/28596237/the-snare-protein-syntaxin1a-plays-an-essential-role-in-biphasic-exocytosis-of-the-incretin-hormone-glucagon-like-peptide-1
#12
Sarah E Wheeler, Holly M Stacey, Yasaman Nahaei, Stephen J Hale, Alexandre B Hardy, Frank Reimann, Fiona M Gribble, Pierre Larraufie, Herbert Y Gaisano, Patricia L Brubaker
Exocytosis of the hormone, glucagon-like peptide-1 (GLP-1), by the intestinal L-cell is essential for the incretin effect after nutrient ingestion, and is critical for the actions of dipeptidylpeptidase IV inhibitors that enhance GLP-1 levels in patients with type 2 diabetes. 2-Photon microscopy revealed that exocytosis of GLP-1 is biphasic, with a 1(st) peak at 1-6min and a 2(nd) peak at 7-12min after stimulation with forskolin. Approximately 75% of the exocytotic events were represented by compound granule fusion, and the remainder were accounted for by full fusion of single granules, under basal and stimulated conditions...
June 8, 2017: Diabetes
https://www.readbyqxmd.com/read/28595187/rs10767664-gene-variant-in-brain-derived-neurotrophic-factor-is-associated-with-diabetes-mellitus-type-2-in-caucasian-females-with-obesity
#13
Daniel Antonio de Luis, Rocío Aller, Olatz Izaola, David Primo, Enrique Romero
BACKGROUND: The role of brain-derived neurotrophic factor (BDNF) variants on diabetes prevalence, basal adipokine levels, body weight, and cardiovascular risk factors remains unclear in obese patients. OBJECTIVE: This study is aimed at analyzing the effects of rs10767664 BDNF gene polymorphism on diabetes mellitus prevalence, body weight, cardiovascular risk factors, and serum adipokine levels in obese female patients. DESIGN: A total of 507 obese women were enrolled in a prospective way...
June 9, 2017: Annals of Nutrition & Metabolism
https://www.readbyqxmd.com/read/28589154/prolonged-ketosis-in-a-patient-with-euglycemic-diabetic-ketoacidosis-secondary-to-dapagliflozin
#14
Shreya Pujara, Adriana Ioachimescu
Since the approval of sodium-glucose cotransporter 2 (SGLT2) inhibitors by the US Food and Drug Administration for type 2 diabetes, there have been several reports of euglycemic diabetic ketoacidosis in patients using this class of medication. We present a case of euglycemic diabetic ketoacidosis where ketonemia and glucosuria persisted well beyond the expected effect of dapagliflozin. Our patient is a 50-year-old woman with type 2 diabetes since age 35 who was taking metformin and dapagliflozin. She presented with fatigue, constipation, and 3 days of reduced oral intake...
April 2017: Journal of Investigative Medicine High Impact Case Reports
https://www.readbyqxmd.com/read/28587789/once-weekly-glucagon-like-peptide-1-receptor-agonist-albiglutide-vs-prandial-insulin-added-to-basal-insulin-in-patients-with-type-2-diabetes-mellitus-results-over-52-weeks
#15
Lawrence A Leiter, Jorge Luiz Gross, Francis Chow, Diane Miller, Susan Johnson, Bo Ahrén
We have previously reported that once-weekly albiglutide was noninferior to thrice-daily lispro for glycemic lowering, with decreased weight and risk of hypoglycemia, in patients inadequately controlled on basal insulin over 26 weeks. Findings after 52 weeks reveal similar responses to albiglutide as an add-on to insulin glargine.
May 25, 2017: Journal of Diabetes and its Complications
https://www.readbyqxmd.com/read/28587667/the-effects-of-basal-insulin-peglispro-vs-insulin-glargine-on-lipoprotein-particles-by-nmr-and-liver-fat-content-by-mri-in-patients-with-diabetes
#16
Trevor J Orchard, Bertrand Cariou, Margery A Connelly, James D Otvos, Shuyu Zhang, Caryl J Antalis, Tibor Ivanyi, Byron J Hoogwerf
BACKGROUND: In Phase 2/3 studies of basal insulin peglispro (BIL) compared to insulin glargine, patients with type 1 or type 2 diabetes previously treated with insulin and randomized to BIL had an increase in serum triglycerides (TGs). To further understand lipoprotein changes, a lipid substudy which included liver fat content was designed to assess relationships among the measured variables for each diabetes cohort and compare the hepato-preferential insulin BIL to glargine. METHODS: In three cohorts of patients with diabetes (type 1, type 2 insulin naïve, and type 2 previously on insulin; n = 652), liver fat content (LFC) was determined by magnetic resonance imaging (MRI) and blood lipids were analyzed by nuclear magnetic resonance (NMR) spectroscopy at baseline, 26 and 52 weeks of treatment...
June 6, 2017: Cardiovascular Diabetology
https://www.readbyqxmd.com/read/28586529/reproducibility-of-the-plasma-glucose-response-to-moderate-intensity-exercise-in-adolescents-with-type-1-diabetes
#17
M B Abraham, R J Davey, M N Cooper, N Paramalingam, M J O'Grady, T T Ly, T W Jones, P A Fournier, E A Davis
AIMS: The aim of the study was to evaluate the reproducibility of the plasma glucose response to moderate-intensity exercise performed on different days under controlled conditions in adolescents with Type 1 diabetes. METHODS: Eight adolescents with Type 1 diabetes on continuous subcutaneous insulin infusion completed two exercise sessions, each on two separate days, under basal insulin and fasting conditions. On each day, participants cycled twice for 30 min at 55% of their peak rate of oxygen consumption, with each exercise session separated by a 30-min rest...
June 6, 2017: Diabetic Medicine: a Journal of the British Diabetic Association
https://www.readbyqxmd.com/read/28586518/combination-therapy-with-multiple-oral-hypoglycaemic-agents-together-with-short-term-basal-insulin-in-new-onset-type-2-diabetes-mellitus-with-marked-hyperglycaemia
#18
S Ray, J J Mukherjee
Type 2 diabetes mellitus is characterized by the relentless loss of β-cell function, which is partly attributable to glucotoxicity and lipotoxicity. Prolonged exposure to excess glucose and oxidative stress leads to β-cell destruction [1,2]. Evidence suggests that early intensive intervention to achieve normoglycaemia can preserve β-cell function, probably by correcting glucotoxicity and lipotoxicity [3]. This article is protected by copyright. All rights reserved.
June 6, 2017: Diabetic Medicine: a Journal of the British Diabetic Association
https://www.readbyqxmd.com/read/28581207/improving-postprandial-hyperglycemia-in-patients-with-type-2-diabetes-already-on-basal-insulin-therapy-a-review-of-current-strategies
#19
REVIEW
Guillermo E Umpierrez, Timothy S Bailey, Danielle Carcia, Charles Shaefer, Jay H Shubrook, Neil Skolnik
A large number of patients with type 2 diabetes (T2D) on basal insulin do not reach their glycosylated hemoglobin A1c (HbA1c) goals and require additional therapy to address postprandial hyperglycemia. Guidelines from expert bodies have outlined several approaches to accomplish post-prandial glucose (PPG) control, and recent literature suggests several more. This article provides strategies for primary care physicians caring for patients with T2D who do not achieve glycemic control with basal insulin alone...
June 5, 2017: Journal of Diabetes
https://www.readbyqxmd.com/read/28574177/review-of-basal-plus-insulin-regimen-options-for-simpler-insulin-intensification-in-people-with-type-2-diabetes-mellitus
#20
REVIEW
D Raccah, D Huet, A Dib, F Joseph, B Landers, J Escalada, H Schmitt
AIMS: To identify simple insulin regimens for people with Type 2 diabetes mellitus that can be accepted and implemented earlier in primary and specialist care, taking into consideration each individual's needs and capabilities. METHODS: Using randomized clinical trials identified by a search of the PubMed database, as well as systematic reviews, meta-analyses and proof-of-concept studies, this review addresses topics of interest related to the progressive intensification of a basal insulin regimen to a basal-plus regimen (one basal insulin injection plus stepwise addition of one to three preprandial short-acting insulin injections/day) vs a basal-bolus regimen (basal insulin plus three short-acting insulin injections per day) in people with Type 2 diabetes...
June 2, 2017: Diabetic Medicine: a Journal of the British Diabetic Association
keyword
keyword
32685
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"